DBV Stock Analysis: DBV Technologies S.A. | PA
Biotechnology | PA, France | Market Cap: 856m EUR | 12M Return: 56% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 2.33M
Qual. Beats: 0
Rev. Trend: -43.3%
Qual. Beats: -1
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
DBV Technologies S.A. is a clinical-stage French biopharmaceutical company focused on epicutaneous immunotherapy, a method that delivers allergens through the skin via patch technology. Founded in 2002 and headquartered in Châtillon, France, the companys lead candidate, Viaskin Peanut, has completed Phase 3 clinical trials for peanut allergy treatment, while Viaskin Milk is in Phase 1/2 trials targeting cows milk protein allergy and eosinophilic esophagitis. Earlier-stage research targets celiac disease, and the company maintains a broader Viaskin technology platform aimed at additional food allergy indications. DBV also collaborates with Nestlé Health Science to develop MAG1C, a diagnostic patch test for non-IgE mediated cows milk protein allergy in infants and toddlers.
As a clinical-stage biotechnology company, DBV has no commercially approved products and therefore does not generate meaningful product revenue; its operations are typically funded through equity raises, grants, and development partnerships. Epicutaneous immunotherapy represents a needle-free, non-systemic alternative to oral or subcutaneous allergy treatments, positioning DBV within a niche but growing segment of the allergy and immunology therapeutics market.
- Viaskin Peanut FDA approval decision remains primary stock catalyst
- Cash burn accelerates as clinical-stage pipeline lacks product revenue
- Nestlé MAG1C patch test partnership progresses in pediatric CMPA diagnosis
| Net Income: -167.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.57 > 0.02 and ΔFCF/TA 121.8 > 1.0 |
| NWC/Revenue: 3.46k% < 20% (prev -321.3%; Δ 3.78k% < -1%) |
| CFO/TA -0.57 > 3% & CFO -151.1m > Net Income -167.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.76 > 1.5 & < 3 |
| Outstanding Shares: last quarter (428.3m) vs 12m ago 317.4% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 3.56% > 50% (prev 6.92%; Δ -3.36% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.73 (Total Current Assets 246.7m - Total Current Liabilities 51.8m) / Total Assets 266.4m |
| B: -1.65 (Retained Earnings -440.7m / Total Assets 266.4m) |
| C: -1.08 (EBIT TTM -170.9m / Avg Total Assets 158.5m) |
| D: 3.56 (Book Value of Equity 208.0m / Total Liabilities 58.5m) |
| Altman-Z'' = -4.11 = D |
| DSRI: 0.76 (Receivables 15.1m/12.3m, Revenue 5.64m/3.50m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.21 (AQ_t 0.02 / AQ_t-1 0.10) |
| SGI: 1.61 (Revenue 5.64m / 3.50m) |
| TATA: -0.06 (NI -167.7m - CFO -151.1m) / TA 266.4m) |
| Beneish M = -3.26 (Cap -4..+1) = AA |
As of July 08, 2026, the stock is trading at EUR 2.87 with a total of 689,195 shares traded. Over the past week, the price has changed by +1.91%, over one month by +1.20%, over three months by -18.54% and over the past year by +56.03%.
Current recommended Stop Loss: 2.40 (which is 16.4% or 2.6 ATR below the current price).
DBV Technologies S.A. has no consensus analysts rating.
Market Cap USD = 976.8m (856.4m EUR * 1.1405 EUR.USD)
P/S = 149.3081
P/B = 4.689
Revenue TTM = 5.64m USD
EBIT TTM = -170.9m USD
EBITDA TTM = -158.2m USD
Long Term Debt = 5.41m USD (from longTermDebtTotal, last fiscal year)
Short Term Debt = 12.2m USD (from shortTermDebt, last quarter)
Debt = 6.10m USD (from shortLongTermDebtTotal, last quarter) (leases 6.10m already included)
Net Debt = -223.1m USD (calculated: Debt 6.10m - CCE 229.2m)
Enterprise Value = 753.7m USD (976.8m + Debt 6.10m - CCE 229.2m)
Interest Coverage Ratio = unknown (Ebit TTM -170.9m / Interest Expense TTM 0.0)
EV/FCF = -4.96x (Enterprise Value 753.7m / FCF TTM -152.1m)
FCF Yield = -20.18% (FCF TTM -152.1m / Enterprise Value 753.7m)
FCF Margin = -2.70k% (FCF TTM -152.1m / Revenue TTM 5.64m)
Net Margin = -2.98k% (Net Income TTM -167.7m / Revenue TTM 5.64m)
Gross Margin = unknown ((Revenue TTM 5.64m - Cost of Revenue TTM 18.3m) / Revenue TTM)
Tobins Q-Ratio = 2.83 (Enterprise Value 753.7m / Total Assets 266.4m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 6.10m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -135.0m (EBIT -170.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.76 (Total Current Assets 246.7m / Total Current Liabilities 51.8m)
Debt / Equity = 0.03 (Debt 6.10m / totalStockholderEquity, last quarter 208.0m)
Debt / EBITDA = 1.41 (negative EBITDA) (Net Debt -223.1m / EBITDA -158.2m)
Debt / FCF = 1.47 (negative FCF - burning cash) (Net Debt -223.1m / FCF TTM -152.1m)
Total Stockholder Equity = 129.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -105.8% (out of range, set to none)
RoE = -130.1% (Net Income TTM -167.7m / Total Stockholder Equity 129.0m)
RoCE = -127.2% (out of range, set to none) (EBIT -170.9m / Capital Employed (Equity 129.0m + L.T.Debt 5.41m))
RoIC = -59.61% (negative operating profit) (NOPAT -135.0m / Invested Capital 226.5m)
WACC = 6.54% (E(976.8m)/V(982.9m) * Re(6.58%) + D(6.10m)/V(982.9m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 6.58% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 69.01 | Cagr: 94.31%
[DCF] Fair Price = unknown (Cash Flow -152.1m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.52 | # QB: 0
Revenue Correlation: -43.25 | Revenue CAGR: -24.14% | SUE: -1.09 | # QB: -1
EPS current Quarter (2026-06-30): EPS=-0.09 | Chg30d=+18.27% | Revisions=+25% | Analysts=1
EPS next Quarter (2026-09-30): EPS=-0.08 | Chg30d=+10.47% | Revisions=+25% | Analysts=1
EPS current Year (2026-12-31): EPS=-0.34 | Chg30d=-1.48% | Revisions=-25% | GrowthEPS=+24.6% | GrowthRev=-22.8%
EPS next Year (2027-12-31): EPS=-0.15 | Chg30d=-1.39% | Revisions=-25% | GrowthEPS=+57.4% | GrowthRev=+2028.0%